CD274 and hepatocellular carcinoma: In unresectable hepatocellular carcinoma (HCC) and metastatic NSCLC patients, a first-line combined therapy of chemotherapy, bevacizumab, and the anti-PD-L1 mAb atezolizumab is superior to that of chemotherapy plus anti-angiogenesis treatment alone (69, 70) (more examples in Supplementary Table 1).